中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 1
Jan.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(1): 193-198

Research advances in the immunomodulatory mechanism of galectin-9 and its role in liver diseases

DOI: 10.12449/JCH240132
  • 1.

    Guizhou Provincial Key Laboratory of Cell Engineering，Affiliated Hospital of Zunyi Medical University，Zunyi，Guizhou 563003，China

  • 2.

    Division of Liver Disease，The Fifth Medical Center of Chinese PLA General Hospital，Beijing 100039，China

Research funding:

National Science and Technology Major Project (2017ZX10203201);

Funded Projects of National Key R & D Program (2021YFC2301801)

More Information
  • Corresponding author: YU Limei， ylm720@sina.com （ORCID： 0000-0002-3377-1202）; YOU Shaoli， youshaoli1972@163.com （ORCID： 0000-0001-8689-8509）
  • Received Date: 2023-04-18
  • Accepted Date: 2023-05-23
  • Published Date: 2024-01-23
    Abstract
  • Galectin-9 （Gal-9） is a member of the galectin family that can specifically recognize and bind to galactosides. Recent studies have shown that Gal-9 is highly expressed in the liver and can help to maintain intrahepatic immune homeostasis and perform biological functions in various liver diseases. This article reviews the immunomodulatory functions of Gal-9 and its role in different liver diseases. Studies have shown that Gal-9 has important biological functions in different liver diseases through multiple pathways. Research on the specific immunomodulatory mechanisms and functions of Gal-9 may help to discover the therapeutic role of Gal-9 in liver diseases.

     

    • FullText(HTML)
  • loading
    • References(45)
  • [1]
    TÜRECI O, SCHMITT H, FADLE N, et al. Molecular definition of a novel human galectin which is immunogenic in patients with Hodgkin’s disease[J]. J Biol Chem, 1997, 272( 10): 6416- 6422. DOI: 10.1074/jbc.272.10.6416.
    [2]
    LIU D, ZHU HT, LI CZ. Galectins and galectin-mediated autophagy regulation: New insights into targeted cancer therapy[J]. Biomark Res, 2023, 11( 1): 22. DOI: 10.1186/s40364-023-00466-9.
    [3]
    BI SG, EARL LA, JACOBS L, et al. Structural features of galectin-9 and galectin-1 that determine distinct T cell death pathways[J]. J Biol Chem, 2008, 283( 18): 12248- 12258. DOI: 10.1074/jbc.M800523200.
    [4]
    JIAO JH, JIAO D, YANG F, et al. Galectin-9 expression predicts poor prognosis in hepatitis B virus-associated hepatocellular carcinoma[J]. Aging, 2022, 14( 4): 1879- 1890. DOI: 10.18632/aging.203909.
    [5]
    MOAR P, TANDON R. Galectin-9 as a biomarker of disease severity[J]. Cell Immunol, 2021, 361: 104287. DOI: 10.1016/j.cellimm.2021.104287.
    [6]
    MONNEY L, SABATOS CA, GAGLIA JL, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease[J]. Nature, 2002, 415( 6871): 536- 541. DOI: 10.1038/415536a.
    [7]
    LI YR. Mechanisms of gal-9/tim-3 mediated immune regulation[D]. Beijing: Academy of Military Medical Sciences, 2011.

    李育蓉. Gal-9/Tim-3通路介导免疫调节的机制研究[D]. 北京: 中国人民解放军军事医学科学院, 2011.
    [8]
    KANDEL S, ADHIKARY P, LI GF, et al. The TIM3/Gal9 signaling pathway: An emerging target for cancer immunotherapy[J]. Cancer Lett, 2021, 510: 67- 78. DOI: 10.1016/j.canlet.2021.04.011.
    [9]
    HARWOOD NMK, GOLDEN-MASON L, CHENG LL, et al. HCV-infected cells and differentiation increase monocyte immunoregulatory galectin-9 production[J]. J Leukoc Biol, 2016, 99( 3): 495- 503. DOI: 10.1189/jlb.5A1214-582R.
    [10]
    NACE GW, HUANG H, KLUNE JR, et al. Cellular-specific role of toll-like receptor 4 in hepatic ischemia-reperfusion injury in mice[J]. Hepatology, 2013, 58( 1): 374- 387. DOI: 10.1002/hep.26346.
    [11]
    WANG F, XU J, LIAO YL, et al. Tim-3 ligand galectin-9 reduces IL-17 level and accelerates Klebsiella pneumoniae infection[J]. Cell Immunol, 2011, 269( 1): 22- 28. DOI: 10.1016/j.cellimm.2011.03.005.
    [12]
    ZHIVOTOVSKY B, BURGESS DH, VANAGS DM, et al. Involvement of cellular proteolytic machinery in apoptosis[J]. Biochem Biophys Res Commun, 1997, 230( 3): 481- 488. DOI: 10.1006/bbrc.1996.6016.
    [13]
    KASHIO Y, NAKAMURA K, ABEDIN MJ, et al. Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway[J]. J Immunol, 2003, 170( 7): 3631- 3636. DOI: 10.4049/jimmunol.170.7.3631.
    [14]
    EGGENHUIZEN PJ, NG BH, OOI JD. Treg enhancing therapies to treat autoimmune diseases[J]. Int J Mol Sci, 2020, 21( 19): 7015. DOI: 10.3390/ijms21197015.
    [15]
    WANG F, WAN LG, ZHANG CC, et al. Tim-3-Galectin-9 pathway involves the suppression induced by CD4+CD25+ regulatory T cells[J]. Immunobiology, 2009, 214( 5): 342- 349. DOI: 10.1016/j.imbio.2008.10.007.
    [16]
    MENGSHOL JA, GOLDEN-MASON L, ARIKAWA T, et al. A crucial role for Kupffer cell-derived galectin-9 in regulation of T cell immunity in hepatitis C infection[J]. PLoS One, 2010, 5( 3): e9504. DOI: 10.1371/journal.pone.0009504.
    [17]
    SEKI M, OOMIZU S, SAKATA KM, et al. Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis[J]. Clin Immunol, 2008, 127( 1): 78- 88. DOI: 10.1016/j.clim.2008.01.006.
    [18]
    LV K, ZHANG YY, ZHANG MY, et al. Galectin-9 ameliorates Con A-induced hepatitis by inducing CD4(+‍)CD25(low/int) effector T-cell apoptosis and increasing regulatory T cell number[J]. PLoS One, 2012, 7( 10): e48379. DOI: 10.1371/journal.pone.0048379.
    [19]
    DONG Y, YANG CP, PAN F. Post-translational regulations of Foxp3 in treg cells and their therapeutic applications[J]. Front Immunol, 2021, 12: 626172. DOI: 10.3389/fimmu.2021.626172.
    [20]
    MO R, FENG XX, WU YN, et al. Hepatocytes paradoxically affect intrahepatic IFN-γ production in autoimmune hepatitis due to Gal-9 expression and TLR2/4 ligand release[J]. Mol Immunol, 2020, 123: 106- 115. DOI: 10.1016/j.molimm.2020.05.014.
    [21]
    RANSON T, VOSSHENRICH CAJ, CORCUFF E, et al. IL-15 availability conditions homeostasis of peripheral natural killer T cells[J]. Proc Natl Acad Sci USA, 2003, 100( 5): 2663- 2668. DOI: 10.1073/pnas.0535482100.
    [22]
    TANG ZH, LIANG SW, POTTER J, et al. Tim-3/galectin-9 regulate the homeostasis of hepatic NKT cells in a murine model of nonalcoholic fatty liver disease[J]. J Immunol, 2013, 190( 4): 1788- 1796. DOI: 10.4049/jimmunol.1202814.
    [23]
    ZENG XJ. Expression and clinical significance of tim-3/galectin-9 signaling pathway in acute leukemia[D]. Urumqi: Xinjiang Medical University, 2021.

    曾雪娇. Tim-3/Galectin-9信号通路在急性白血病上的表达及临床意义[D]. 乌鲁木齐: 新疆医科大学, 2021.
    [24]
    YANG Y, DONG D, XUE QW, et al. Correlation of negative molecules Tim-3 and Galectin-9 with clinicopathological characteristics of cervical cancer[J]. J Xinjiang Med Univ, 2020, 43( 8): 1004- 1008. DOI: 10.3969/j.issn.1009-5551.2020.08.003.

    杨艳, 董頔, 薛茜文, 等. 负性分子Tim-3和Galectin-9与宫颈癌患者临床病理特征的相关性研究[J]. 新疆医科大学学报, 2020, 43( 8): 1004- 1008. DOI: 10.3969/j.issn.1009-5551.2020.08.003.
    [25]
    COLOMB F, GIRON LB, PREMEAUX TA, et al. Galectin-9 mediates HIV transcription by inducing TCR-dependent ERK signaling[J]. Front Immunol, 2019, 10: 267. DOI: 10.3389/fimmu.2019.00267.
    [26]
    MANSOUR AA, RAUCCI F, SAVIANO A, et al. Galectin-9 regulates monosodium urate crystal-induced gouty inflammation through the modulation of treg/Th17 ratio[J]. Front Immunol, 2021, 12: 762016. DOI: 10.3389/fimmu.2021.762016.
    [27]
    UCHIDA Y, KE BB, FREITAS MCS, et al. T-cell immunoglobulin mucin-3 determines severity of liver ischemia/reperfusion injury in mice in a TLR4-dependent manner[J]. Gastroenterology, 2010, 139( 6): 2195- 2206. DOI: 10.1053/j.gastro.2010.07.003.
    [28]
    TSUNG A, SAHAI R, TANAKA H, et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion[J]. J Exp Med, 2005, 201( 7): 1135- 1143. DOI: 10.1084/jem.20042614.
    [29]
    ZHAI Y, SHEN XD, O’CONNELL R, et al. Cutting edge: TLR4 activation mediates liver ischemia/reperfusion inflammatory response via IFN regulatory factor 3-dependent MyD88-independent pathway[J]. J Immunol, 2004, 173( 12): 7115- 7119. DOI: 10.4049/jimmunol.173.12.7115.
    [30]
    ZHAO LZ, LIANG J, RAO W, et al. Cross-regulation by TLR4 and T cell Ig mucin-3 determines severity of liver injury in a CCl4-induced mouse model[J]. Scand J Immunol, 2020, 91( 4): e12851. DOI: 10.1111/sji.12851.
    [31]
    LIU YX, JI HF, ZHANG Y, et al. Recipient T cell TIM-3 and hepatocyte galectin-9 signalling protects mouse liver transplants against ischemia-reperfusion injury[J]. J Hepatol, 2015, 62( 3): 563- 572. DOI: 10.1016/j.jhep.2014.10.034.
    [32]
    HASSAN A, FONTANA RJ. The diagnosis and management of idiosyncratic drug-induced liver injury[J]. Liver Int, 2019, 39( 1): 31- 41. DOI: 10.1111/liv.13931.
    [33]
    ROSEN HR, BIGGINS SW, NIKI T, et al. Association between plasma level of galectin-9 and survival of patients with drug-induced acute liver failure[J]. Clin Gastroenterol Hepatol, 2016, 14( 4): 606- 612.e3. DOI: 10.1016/j.cgh.2015.09.040.
    [34]
    ROSEN HR. Emerging concepts in immunity to hepatitis C virus infection[J]. J Clin Invest, 2013, 123( 10): 4121- 4130. DOI: 10.1172/JCI67714.
    [35]
    YANG XF, WANG LX, HUANG CX, et al. Mechanism of gamma-chain cytokines in regulating the expression of T-cell immunoglobulin and mucin domain-containing molecule 3 in CD8+ T cells of chronic hepatitis B patients[J]. J Clin Hepatol, 2021, 37( 5): 1059- 1064. DOI: 10.3969/j.issn.1001-5256.2021.05.017.

    杨晓飞, 王临旭, 黄长形, 等. γ链细胞因子对慢性乙型肝炎患者T淋巴细胞免疫球蛋白黏蛋白分子3表达调控的诱导机制[J]. 临床肝胆病杂志, 2021, 37( 5): 1059- 1064. DOI: 10.3969/j.issn.1001-5256.2021.05.017.
    [36]
    NEBBIA G, PEPPA D, SCHURICH A, et al. Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection[J]. PLoS One, 2012, 7( 10): e47648. DOI: 10.1371/journal.pone.0047648.
    [37]
    GOLDEN-MASON L, PALMER BE, KASSAM N, et al. Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells[J]. J Virol, 2009, 83( 18): 9122- 9130. DOI: 10.1128/JVI.00639-09.
    [38]
    McMAHAN RH, GOLDEN-MASON L, NISHIMURA MI, et al. Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity[J]. J Clin Invest, 2010, 120( 12): 4546- 57. DOI: 10.1172/JCI43127.
    [39]
    LAI JH, LUO SF, WANG MY, et al. Translational implication of galectin-9 in the pathogenesis and treatment of viral infection[J]. Int J Mol Sci, 2017, 18( 10): 2108. DOI: 10.3390/ijms18102108.
    [40]
    LIU SY, XU C, YANG F, et al. Natural killer cells induce CD8+ T cell dysfunction via galectin-9/TIM-3 in chronic hepatitis B virus infection[J]. Front Immunol, 2022, 13: 884290. DOI: 10.3389/fimmu.2022.884290.
    [41]
    LIBERAL R, GRANT CR, HOLDER BS, et al. The impaired immune regulation of autoimmune hepatitis is linked to a defective galectin-9/tim-3 pathway[J]. Hepatology, 2012, 56( 2): 677- 686. DOI: 10.1002/hep.25682.
    [42]
    JIANG Y, HAN QJ, ZHAO HJ, et al. The mechanisms of HBV-induced hepatocellular carcinoma[J]. J Hepatocell Carcinoma, 2021, 8: 435- 450. DOI: 10.2147/JHC.S307962.
    [43]
    LI H, WU K, TAO KX, et al. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma[J]. Hepatology, 2012, 56( 4): 1342- 1351. DOI: 10.1002/hep.25777.
    [44]
    GOLDEN-MASON L, MCMAHAN RH, STRONG M, et al. Galectin-9 functionally impairs natural killer cells in humans and mice[J]. J Virol, 2013, 87( 9): 4835- 4845. DOI: 10.1128/JVI.01085-12.
    [45]
    FUJITA K, IWAMA H, SAKAMOTO T, et al. Galectin-9 suppresses the growth of hepatocellular carcinoma via apoptosis in vitro and in vivo[J]. Int J Oncol, 2015, 46( 6): 2419- 2430. DOI: 10.3892/ijo.2015.2941.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (161) PDF downloads(15) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return